Price target by analysts
The 2 latest analyst estimates, per Thursday 4 June, 2020, show the following high, low and average price targets.
Target Average: 10 USD
Target High: 11 USD
Target Low: 9 USD
INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Amyris, Inc. – AMRS
Wednesday, 29 July 2020, 18:25:00
NEW YORK , July 29, 2020 /PRNewswire/ — Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City , is investigating Amyris, Inc. (“Amyris” or the “Company”) (Nasdaq: AMRS) relating to the Company’s June 1 and June 4, 2020 financing transactions, which permit Foris Ventures, LLC to obtain Amyris common stock. Under the terms of the transaction, Amyris shareholders would receive $3.00 for each share of Amyris common stock owned. … Full story available on Benzinga.com
SHAREHOLDER ALERT: WeissLaw LLP Investigates Amyris, Inc.
Wednesday, 29 July 2020, 03:07:00
NEW YORK, July 28, 2020 /PRNewswire/ — URGENT: SHAREHOLDER VOTE AUGUST 14, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Amyris, Inc. (“AMRS” or the “Company”) (NASDAQ: AMRS) in connection with the…
— PR Newswire
Amyris partners with IDRI to create adjuvants for COVID-19 vaccine (NASDAQ:AMRS)
Monday, 27 July 2020, 18:16:31
Amyris (AMRS +4.7%) and Infectious Disease Research Institute (IDRI) has signed a binding term for a planned COVID-19 RNA (ribonucleic acid) vaccine techno
— Seeking Alpha
Why Amyris Is Trading Higher Today
Monday, 27 July 2020, 17:26:05
Amyris (NASDAQ: AMRS ) shares are trading higher on Monday after the company signed a binding term sheet for a planned COVID-19 RNA vaccine technology program with the Infectious Disease Research Institute. Amyris is an industrial biotechnology company. It … Full story available on Benzinga.com
Amyris and The Infectious Disease Research Institute Partner to Advance Novel RNA Vaccine Platform Beginning With COVID-19 Application
Monday, 27 July 2020, 14:30:00
EMERYVILLE, Calif. , July 27, 2020 /PRNewswire/ — Amyris, Inc. (NASDAQ: AMRS ), a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) today announce the signing of a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI’s expertise in combating infectious diseases with Amyris’ fermentation platform technology, with the goal to create semi-synthetic squalene-based adjuvants at scale. IDRI’s RNA vaccine platform is expected to offer significant differentiated advantages over other RNA vaccines currently in development and will be further enhanced by a scalable Amyris adjuvant. The Critical Role of Adjuvants in Vaccines Adjuvants are added to vaccines as an excipient to enhance their effectiveness and are typically sourced from shark-based squalene, a non-sustainable and non-scalable resource. Amyris’ fermentation technology, which replaces shark-derived squalene with lower cost sugarcane-derived squalene, is capable of delivering greater availability facilitating access to adjuvants by large parts of the population.
— Benzinga Feeds